Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease
- 1 June 2022
- journal article
- letter
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 20 (6) , 1408-1410.e2
Abstract
No abstract availableKeywords
Funding Information
- NIH
- National Institute of Diabetes and Digestive and Kidney Diseases (K23 DK119585, R01 DK111843)
This publication has 8 references indexed in Scilit:
- Ruxolitinib in Alleviating the Cytokine Storm of Hemophagocytic LymphohistiocytosisPediatrics, 2020
- Ruxolitinib Response in an Infant With Very‐early‐onset Inflammatory Bowel Disease and Gain‐of‐function STAT1 MutationJournal of Pediatric Gastroenterology and Nutrition, 2020
- JAK–STAT pathway targeting for the treatment of inflammatory bowel diseaseNature Reviews Gastroenterology & Hepatology, 2020
- North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper on the Evaluation and Management for Patients With Very Early‐onset Inflammatory Bowel DiseaseJournal of Pediatric Gastroenterology and Nutrition, 2020
- Jakinibs for the treatment of immune dysregulation in patients with gain-of-function signal transducer and activator of transcription 1 (STAT1) or STAT3 mutationsJournal of Allergy and Clinical Immunology, 2018
- Heterozygous STAT1 gain-of-function mutations underlie an unexpectedly broad clinical phenotypeBlood, 2016
- Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function MutationClinical Infectious Diseases, 2016
- The Diagnostic Approach to Monogenic Very Early Onset Inflammatory Bowel DiseaseGastroenterology, 2014